Alzai Health

What Alzai Health does

Alzai Health Corp. is a publicly traded digital health company (TSX-V: ALZI, IPO June 2026) that has developed a non-invasive, AI-driven disease risk identification platform anchored by its Alzheimer's disease risk screening solution. The core technology applies proprietary AI algorithms to pre-existing patient data found in every medical record — common blood chemistry laboratory test results and chronic disease diagnostic records — and produces population-level risk stratification quantified by year and confidence level, with prediction horizons up to 10 years. Validated on more than 500,000 patients in production and independently confirmed on a U.S. longitudinal dataset of 1.1 million+ patients covering over 100 million clinical data points, the platform reports 80% sensitivity in identifying mild AD/MCI cases versus 17% under current standard of care. The company has also secured an exclusive worldwide license for an AI-driven liver disease risk identification technology from MOR Research Applications (Clalit Health Services) and Yeda Research (Weizmann Institute), extending the platform into cirrhosis and chronic liver conditions.

The company's go-to-market is enterprise-focused and operates through three revenue streams: (1) licensing of its AI platform for clinical trial pre-screening to pharmaceutical companies, CROs, and research institutions (this use case requires no FDA 510(k) clearance, enabling immediate commercialization); (2) pay-per-screen and annual licensing to large health systems, diagnostic labs, and insurance companies for population-level screening (FDA 510(k) Clinical Decision Support Tool pathway, ~24-month timeline); and (3) royalties and sublicensing income from the liver disease technology. Distribution is direct for global enterprise clients and via a strategic U.S. commercialization agreement with Centauri Health Solutions, whose platform serves 60 million members across U.S. providers and health plans, particularly in Medicare Advantage and value-based care settings. ALZAI is headquartered in Toronto, Canada (incorporated in Ontario, November 15, 2024), with operational and clinical ties to Israel through its founding team's ties to Clalit Health Services and the Weizmann Institute.

Name

Alzai Health

Legal name

ALZAI HEALTH CORP.

Website

https://alzaihealth.com

Company type

Public

Founded year

2024

Operating status

Ipo

Headcount range

1–10 employees

Short description

Alzai Health Corp. is a TSX-V-listed digital health company that develops a non-invasive, AI-driven disease risk identification platform using pre-existing EMR data, initially commercialized for Alzheimer's risk screening and expanded to liver disease risk through an exclusive global license. It sells to pharmaceutical companies, health systems, diagnostic labs, and payors, and distributes in the U.S. via Centauri Health Solutions.

Ownership category

akta.pro rank

Product category

Clinical Decision Support / Healthcare AI Software

NAICS

Medical Laboratories (621511)

SIC

Services-Health Services (8000)

akta.pro industry

PRIMARYHLACANAE

SaMD – Monitoring, Triage & Risk Stratification Software

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

SECONDARYHLAAALAO

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• AI disease risk screening
• Alzheimer's risk assessment
• EMR data analytics
• Clinical trial pre-screening
• Clinical decision support

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

1. Clinical Trials Pre-Screening Licensing: Licensing ALZAI solutions to pharmaceutical companies, CROs, and research institutions for pre-screening subjects in clinical trials. Identifying quality candidates early lowers screen-failure rates and accelerates recruitment. No FDA 510(k) required for this use case, enabling immediate commercialization.
2. Professional Services for Integration and Tuning: Professional services revenue from data integration and tuning when deploying ALZAI solutions into healthcare provider and payor environments. This accompanies the core licensing model.
3. Healthcare Provider and Payor Screening: Pay-per-screen and annual licensing models for large health systems, diagnostic and lab services, and insurance companies. Population-level Alzheimer's risk screening for identifying at-risk and disease-positive patients early, enabling proactive intervention and cost savings. Regulatory pathway: FDA 510(k) Clinical Decision Support Tool, approximately 24-month timeline.
4. Liver Disease Risk Technology Licensing and Royalties: Royalties from MOR and Yeda based on future commercialization revenues generated from liver disease products, plus a portion of revenues received through sublicensing arrangements. ALZAI holds exclusive worldwide sublicensable rights to develop, commercialize, and sublicense the licensed liver disease technology.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Alzai Health develops and licenses an AI-driven, non-invasive disease risk identification platform that processes pre-existing Electronic Medical Record (EMR) data—specifically routine blood chemistry lab tests and chronic disease diagnostic records—to stratify patients by Alzheimer's disease risk across multi-year horizons. The platform is offered to pharmaceutical companies and CROs for clinical trial pre-screening, to healthcare providers and payors for population-level screening, and has been expanded via an exclusive worldwide license to include AI-driven liver disease risk identification technology.

Product overview

ALZAI Health offers a unified AI-driven disease risk identification platform centered on its core Alzheimer's Disease risk screening solution. The platform analyzes routine healthcare data from electronic medical records to deliver non-invasive, population-level risk assessment enabling early detection and prevention. The company has expanded its portfolio through an exclusive license for liver disease risk identification technology, creating a multi-disease platform approach. ALZAI's solutions are designed for integration into existing healthcare infrastructure including EMR systems and cloud environments, serving clinical trials, healthcare providers, payors, and individuals.

Differentiator

Problem solved

Functional benefit

Products and services

• ALZAI Alzheimer's Disease Risk Screening Solution AI-driven, non-invasive Alzheimer's disease risk screening tool that analyzes pre-existing patient data from electronic medical records to identify patients in early disease stages or at elevated risk of developing the disease in the coming years. The solution integrates directly into EMR systems or cloud environments to enable population-level risk screening with risk scores stratified by year and quantified by confidence level. Targets pharmaceutical companies, CROs, healthcare systems, diagnostic labs, and insurance companies.
• AI-Driven Liver Disease Risk Identification Technology Proprietary AI technology exclusively licensed worldwide to identify individuals at elevated risk of liver-associated diseases including cirrhosis and other chronic liver conditions using routine healthcare data. Derived from algorithms developed by Clalit Health Services and the Weizmann Institute of Science, and available with sublicensing rights.

Quantifiable outcome

• 80% of mild AD/MCI cases identified vs. 17% under standard of care
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• MOR Research Applications Ltd.coreTechnology or Integration · 20 July 2026ALZAI entered into an exclusive worldwide sublicensable license agreement with MOR Research Applications Ltd. (technology transfer company of Clalit Health Services) and Yeda Research and Development Co. Ltd. (Weizmann Institute of Science) for proprietary AI-driven liver disease risk identification technology. ALZAI will pay customary royalties and a portion of sublicensing revenues. The technology identifies individuals at elevated risk of liver-associated diseases including cirrhosis and chronic liver conditions using routine healthcare data.
• Centauri Health SolutionscoreStrategic or Co-development Partner · 2 July 2026Strategic teaming agreement for U.S. commercialization of ALZAI's AI-driven Alzheimer's disease risk stratification. Centauri serves 60 million members and has national relationships with providers and health plans across Medicare Advantage and value-based care settings. Centauri and ALZAI collaborate to market AI-driven risk stratification to identify patients at high risk for early-stage undiagnosed Alzheimer's Disease, combining Centauri's market access with ALZAI's proprietary AI platform.
• HealthVerityminorOthers · 1 January 2026HealthVerity, a leading provider of real-world healthcare data in the United States, provided a large-scale U.S. longitudinal healthcare dataset used for validation of ALZAI's Alzheimer's disease risk identification models. The dataset covered more than 1.1 million U.S. patients with approximately 38 million blood chemistry lab test results and over 3 million chronic disease diagnostic records. HealthVerity did not participate in development, validation methodology, analysis, or conclusions.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Flatiron Health: Flatiron Health aggregates real-world clinical data and builds oncology-focused clinical decision support and EHR-linked analytics. It is comparable to ALZAI as a platform that uses real-world EMR data and AI to deliver clinical insight, though focused on oncology rather than neurology.
• Tempus Labs: Tempus is a large AI-driven precision medicine company that analyzes clinical and molecular data to support diagnostics, including in oncology and increasingly other disease areas. It is a broader incumbent offering AI-enabled clinical decision support at scale, comparable in platform approach if not in disease focus.
• Optum / UnitedHealth (Healthcare Analytics): Optum combines massive payer claims and clinical data with AI-driven risk stratification, care management, and clinical decision support tools. It is a broad incumbent comparable to ALZAI in applying large-scale healthcare data and AI for population risk stratification and care management, particularly for payors and value-based care.
• Roche / Genentech Diagnostics: Roche/Genentech is developing and commercializing blood-based Alzheimer's diagnostic assays (e.g., Elecsys pTau217) and is a major pharma/diagnostics player. It is a broad incumbent in the same end market — Alzheimer's diagnostics and clinical trial pre-screening — that ALZAI addresses.

Direct peers

• C2N Diagnostics: C2N Diagnostics develops blood-based biomarker tests (PrecivityAD) for early Alzheimer's detection. Like ALZAI, it targets earlier, less-invasive Alzheimer's diagnosis and works with pharma for clinical trial pre-screening, making it a directly comparable blood/AI-based diagnostic peer.
• Quanterix: Quanterix provides ultra-sensitive immunoassay platforms (Simoa) used for blood-based biomarker detection in Alzheimer's and other neurodegenerative diseases. It is comparable to ALZAI as a tool provider enabling non-invasive, blood-based disease risk and detection in research and clinical settings.
• Cogstate: Cogstate offers computerized cognitive testing used in Alzheimer's clinical trials and clinical care. It directly overlaps with ALZAI's clinical trial pre-screening use case and its broader goal of enabling earlier, less-invasive identification of cognitive impairment.

Emerging players

• Neurotrack Technologies: Neurotrack builds digital cognitive assessments and blood-based biomarker tools to detect and monitor cognitive decline and Alzheimer's risk. It overlaps with ALZAI in targeting earlier, non-invasive Alzheimer's risk identification for consumers, providers, and clinical trials.
• Altoida: Altoida develops digital cognitive assessment tools (using AR/AI on smartphones/tablets) for early detection of mild cognitive impairment and Alzheimer's risk. It competes with ALZAI for population-level, non-invasive early Alzheimer's risk identification, though via a different data modality.

Others

• Datavant / HealthVerity ecosystem: HealthVerity (ALZAI's data validation partner) and Datavant provide large-scale de-identified US healthcare data for research and AI validation. They are comparable as data infrastructure enablers in the same real-world-data/AI ecosystem, supporting clinical and commercial AI development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ALZAIHealth
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/alzai-health
• Instagraminstagram.com/alzaihelath

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzai Health